Notch1  ablation radiosensitizes glioblastoma cells

Na Han; Guangyuan Hu; Lei Shi; Guoxian Long; Lin Yang; Qingsong Xi; Qiuyun Guo; Jianhua Wang; Zhen Dong; Mengxian Zhang

doi:10.18632/oncotarget.21409

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Notch1 ablation radiosensitizes glioblastoma cells

Na Han, Guangyuan Hu, Lei Shi, Guoxian Long, Lin Yang, Qingsong Xi, Qiuyun Guo, Jianhua Wang, Zhen Dong and Mengxian Zhang _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:88059-88068. https://doi.org/10.18632/oncotarget.21409

Metrics: PDF 1527 views | HTML 2372 views | ?

Abstract

Na Han1, Guangyuan Hu1, Lei Shi1, Guoxian Long1, Lin Yang1, Qingsong Xi1, Qiuyun Guo1, Jianhua Wang1, Zhen Dong1 and Mengxian Zhang1

1Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China

Correspondence to:

Mengxian Zhang, email: [email protected]

Keywords: glioblastoma, Notch1, CRISPR/Cas9, radiosensitivity, angiogenesis

Received: July 14, 2017 Accepted: September 04, 2017 Published: September 30, 2017

ABSTRACT

Broad specific Notch1 inhibitors suppress glioblastoma multiforme (GBM) growth but have significant gastrointestinal toxicities. Here, we examined Notch1 expression in GBM tissue specimens and its correlation with the overall survival (OS) of GBM patients. Furthermore, using the CRISPR/Cas9 system, we investigated the effects of Notch1 downregulation on clonogenic growth and angiogenesis of GBM cells and xenografts. Immunohistochemistry showed positive Notch1 expression in 71% (49/69) of GBM tissues. Our multivariate Cox regression analysis further revealed that Notch1 expression was an independent adverse prognostic factor for OS. Notch1 downregulation suppressed the growth of GBM cells U87MG and U251. The mean duration to reach 6 x the starting volume was 18.3 days for xenografts with Notch1 downregulation and 13.4 days for the control xenografts. Immunofluorescent staining further disclosed that Notch1 downregulation markedly increased the number of γH2AX foci and radiosensitized GBM cells. Notch1 downregulation also impaired angiogenesis and attenuated VEGF and hypoxic response to irradiation in xenografts. In conclusion, Notch1 ablation inhibited GBM cell proliferation and neovascularization and radiosensitized GBM cells and xenografts, suggesting a pivotal role of Notch1 in tumor growth, angiogenesis, and radioresistance in GBM.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21409

Publication Alerts

Research Papers:

Notch1 ablation radiosensitizes glioblastoma cells

Abstract